3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase NA
2
Phase EARLY_PHASE1
2
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Breast Neoplasms
168
Neoplasms
132
Prostatic Neoplasms
71
Lung Neoplasms
67
Colorectal Neoplasms
65
Motor Activity
39
Uterine Cervical Neoplasms
36
Pancreatic Neoplasms
30
Ovarian Neoplasms
27
Head and Neck Neoplasms
27
Brain Neoplasms
25
Carcinoma, Non-Small-Cell Lung
23
Rectal Neoplasms
21
Glioblastoma
20
Colonic Neoplasms
20
Carcinoma, Hepatocellular
20
Stomach Neoplasms
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Disease
16
Depression
16
Anxiety Disorders
16
Hematologic Neoplasms
15
Melanoma
14
Leukemia
14
Papillomavirus Infections
13
Squamous Cell Carcinoma of Head and Neck
12
Multiple Myeloma
12
Glioma
12
Carcinoma, Renal Cell
12
Urinary Bladder Neoplasms
11
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase NA
×
Immunoglobulin Light-chain Amyloidosis
×
30 days
×
Clear all
NCT05150353
2026-06-04
AMYLOCARP
Ramsay Générale de Santé
Phase NA
Completed
128 enrolled
NCT07624760
2026-06-03
MGUS-PET
University of Zurich
Phase NA
Not yet recruiting
50 enrolled